By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Barbiturate anticonvulsants > Primidone > Primidone Dosage
Barbiturate anticonvulsants
https://themeditary.com/dosage-information/primidone-dosage-6356.html

Primidone Dosage

Drug Detail:Primidone (Primidone [ prim-i-done ])

Drug Class: Barbiturate anticonvulsants

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Epilepsy

For Patients Who Have Not Received Any Previous Treatment:

  • Days 1 to 3: 100 to 125 mg orally at bedtime
  • Days 4 to 6: 100 to 125 mg orally 2 times a day
  • Days 7 to 9: 100 to 125 mg orally 3 times a day
  • Day 10 onward: 250 mg orally 3 to 4 times a day, increasing up to 5 or 6 times a day if necessary
  • Maximum dose: 500 mg orally 4 times a day (2 g daily)

For Patients Already Receiving Other Anticonvulsants:
100 to 125 mg orally at bedtime and gradually increase to maintenance level as the other drug is gradually decreased. Continue this regimen until a satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with this drug alone is the objective, the transition from concomitant therapy should not be completed in less than 2 weeks.

Comments:
  • Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustment. The clinically effective serum level for this drug is between 5 to 12 mcg/mL.
  • This drug may be taken with or without food.

Use: For the control of grand mal, psychomotor, focal, and sometimes grand mal seizures refractory to other anticonvulsant therapy, given alone or concomitantly with other anticonvulsants

Usual Adult Dose for Seizures

For Patients Who Have Not Received Any Previous Treatment:

  • Days 1 to 3: 100 to 125 mg orally at bedtime
  • Days 4 to 6: 100 to 125 mg orally 2 times a day
  • Days 7 to 9: 100 to 125 mg orally 3 times a day
  • Day 10 onward: 250 mg orally 3 to 4 times a day, increasing up to 5 or 6 times a day if necessary
  • Maximum dose: 500 mg orally 4 times a day (2 g daily)

For Patients Already Receiving Other Anticonvulsants:
100 to 125 mg orally at bedtime and gradually increase to maintenance level as the other drug is gradually decreased. Continue this regimen until a satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with this drug alone is the objective, the transition from concomitant therapy should not be completed in less than 2 weeks.

Comments:
  • Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustment. The clinically effective serum level for this drug is between 5 to 12 mcg/mL.
  • This drug may be taken with or without food.

Use: For the control of grand mal, psychomotor, focal, and sometimes grand mal seizures refractory to other anticonvulsant therapy, given alone or concomitantly with other anticonvulsants

Usual Pediatric Dose for Epilepsy

8 years of age and older:

  • For Patients Who Have Not Received Any Previous Treatment:
Days 1 to 3: 100 to 125 mg orally at bedtime
Days 4 to 6: 100 to 125 mg orally 2 times a day
Days 7 to 9: 100 to 125 mg orally 3 times a day
Day 10 onward: 250 mg orally 3 to 4 times a day, increasing up to 5 or 6 times a day if necessary
Maximum dose: 500 mg orally 4 times a day (2 g daily)
  • For Patients Already Receiving Other Anticonvulsants:
100 to 125 mg orally at bedtime and gradually increase to maintenance level as the other drug is gradually decreased. Continue this regimen until a satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with this drug alone is the objective, the transition from concomitant therapy should not be completed in less than 2 weeks.

Less than 8 years:
  • Days 1 to 3: 50 mg orally daily at bedtime
  • Days 4 to 6: 50 mg orally 2 times a day
  • Days 7 to 9: 100 mg orally 2 times a day
  • Day 10 to maintenance: 125 mg orally 3 times a day to 250 mg 3 times a day
  • Usual maintenance dose: 125 to 250 mg orally 3 times daily OR 10 to 25 mg/kg/day orally in divided doses

Comments:
  • Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustment. The clinically effective serum level for this drug is between 5 to 12 mcg/mL.
  • This drug may be taken with or without food.

Use: For the control of grand mal, psychomotor, focal, and sometimes grand mal seizures refractory to other anticonvulsant therapy, given alone or concomitantly with other anticonvulsants

Usual Pediatric Dose for Seizures

8 years of age and older:

  • For Patients Who Have Not Received Any Previous Treatment:
Days 1 to 3: 100 to 125 mg orally at bedtime
Days 4 to 6: 100 to 125 mg orally 2 times a day
Days 7 to 9: 100 to 125 mg orally 3 times a day
Day 10 onward: 250 mg orally 3 to 4 times a day, increasing up to 5 or 6 times a day if necessary
Maximum dose: 500 mg orally 4 times a day (2 g daily)
  • For Patients Already Receiving Other Anticonvulsants:
100 to 125 mg orally at bedtime and gradually increase to maintenance level as the other drug is gradually decreased. Continue this regimen until a satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with this drug alone is the objective, the transition from concomitant therapy should not be completed in less than 2 weeks.

Less than 8 years:
  • Days 1 to 3: 50 mg orally daily at bedtime
  • Days 4 to 6: 50 mg orally 2 times a day
  • Days 7 to 9: 100 mg orally 2 times a day
  • Day 10 to maintenance: 125 mg orally 3 times a day to 250 mg 3 times a day
  • Usual maintenance dose: 125 to 250 mg orally 3 times daily OR 10 to 25 mg/kg/day orally in divided doses

Comments:
  • Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustment. The clinically effective serum level for this drug is between 5 to 12 mcg/mL.
  • This drug may be taken with or without food.

Use: For the control of grand mal, psychomotor, focal, and sometimes grand mal seizures refractory to other anticonvulsant therapy, given alone or concomitantly with other anticonvulsants

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

The total daily dose is usually best divided and given in 2 equal amounts, one in the morning and the other in the evening. In certain patients, it may be preferable to give a larger dose when the seizures are more frequent; for instance: 1) if the attacks are nocturnal then all or most of the day's dose may be given in the evening; 2) if the attacks are associated with some event such as menstruation, a slight increase in the dose may be appropriate.

Precautions

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

This drug is removed by hemodialysis.

Other Comments

Administration advice:

  • This drug may be taken with or without food.

General:
  • It may take several weeks before the therapeutic efficacy of a dosage regimen can be assessed.

Monitoring:
  • The manufacturer recommends a complete blood count (CBC) and sequential multiple analysis 12 (SMA-12) every 6 months that a patient is taking this drug.

Patient advice:
  • Patients and families should be counseled that AEDs can increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by